Abstract Search

ea0073pep8.5 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Osilodrostat provides sustained control of urinary free cortisol in patients with Cushing’s disease: final results from a prospective, open-label study (LINC 2)

Fleseriu Maria , Biller Beverly , Bertherat Jerome , Young Jacques , Arnaldi Giorgio , O’Connell Paul , Izquierdo Miguel , Pedroncelli Alberto , Pivonello Rosario

IntroductionThe oral 11β-hydroxylase inhibitor, osilodrostat, normalized mean urinary free cortisol (mUFC) in 79% (15/19) of patients with Cushings disease at the end of the 22-week core LINC 2 study. Long-term efficacy and safety data following an optional extension phase are reported here.MethodsPatients with clinical benefit at week 22 could continue receiving osilodrostat during the extension; ...

3 shares

ea0073oc8.2 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021

Osilodrostat is an effective and well-tolerated treatment option for patients with Cushing’s disease (CD): Final results from the LINC3 study

Fleseriu Maria , Biller Beverly , Pivonello Rosario , Akira Shimatsu , Carla Scaroni , Belaya Zhanna , Vila Greisa , Houde Ghislaine , Walia Rama , Izquierdo Miguel , Roughton Michael , Pedroncelli Alberto , Newell-Price John

IntroductionOsilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during the 48-week (W) core phase of a Phase III study (LINC3: NCT02180217). We present efficacy and safety results following an extension to LINC3.MethodsCD patients with mUFC > 1.5× upper limit of normal (ULN) received osilodrostat during the core. Patients b...

3 shares

Endocrine Abstracts

Osilodrostat provides sustained control of urinary free cortisol in patients with Cushing’s disease: final results from a prospective, open-label study (LINC 2)

Osilodrostat is an effective and well-tolerated treatment option for patients with Cushing’s disease (CD): Final results from the LINC3 study

BiosciAbstracts